KLK3 and breast carcinoma: Even within larger studies of prostate and breast cancer patients, reports of clinical response outcomes such as radiographic changes, improvement in survival, or decreased biomarkers (including prostate-specific antigen (PSA), cancer antigen 15–3 (CA 15–3), or alkaline phosphatase (AP)) are quite sparse.